Valproate bismuth

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Valproate bismuth
Accession Number
DB13910
Type
Small Molecule
Groups
Approved
Description

Valproate bismuth is available in Canada in the over-the-counter medication Neo-Laryngobis.

Structure
Thumb
Synonyms
  • Bismuth dipropylacetate
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neo Laryngobis EnfSuppositoryRectalLab Bio Chimique Inc.,Division Of Technilab Pharma Inc.1950-12-311997-08-22Canada
Neo-laryngobisSuppositoryRectalTEVA Canada Limited1950-12-31Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
87PTX621FI
CAS number
60364-28-5
Weight
Average: 638.598
Monoisotopic: 638.30201
Chemical Formula
C24H45BiO6
InChI Key
YZDVVHSLIPLZLO-UHFFFAOYSA-K
InChI
InChI=1S/3C8H16O2.Bi/c3*1-3-5-7(6-4-2)8(9)10;/h3*7H,3-6H2,1-2H3,(H,9,10);/q;;;+3/p-3
IUPAC Name
bismuth(3+) tris(2-propylpentanoate)
SMILES
[Bi+3].CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O.CCCC(CCC)C([O-])=O

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Valproate bismuth.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when Valproate bismuth is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Valproate bismuth.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of serotonin syndrome can be increased when Valproate bismuth is combined with 5-methoxy-N,N-dimethyltryptamine.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Valproate bismuth.
AcepromazineAcepromazine may increase the neurotoxic activities of Valproate bismuth.
AceprometazineAceprometazine may increase the neurotoxic activities of Valproate bismuth.
AcetophenazineAcetophenazine may increase the neurotoxic activities of Valproate bismuth.
AlaproclateThe risk or severity of serotonin syndrome can be increased when Alaproclate is combined with Valproate bismuth.
AlfentanilThe risk or severity of serotonin syndrome can be increased when Alfentanil is combined with Valproate bismuth.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
20137751
AHFS Codes
  • 52:92.00 — EENT Drugs, Miscellaneous

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuppositoryRectal
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0716 mg/mLALOGPS
logP6.2ALOGPS
logP2.8ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)5.14ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count15ChemAxon
Refractivity51.09 m3·mol-1ChemAxon
Polarizability16.59 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on September 18, 2017 15:14 / Updated on September 17, 2019 04:03